Document is current

Article History

Received: 2 July 2024

Accepted: 7 February 2025

First Online: 1 March 2025

Declarations

:

: The ESME research program is managed by Unicancer in accordance with current best practice guidelines and rules. It is supervised by a scientific independent steering committee. The ESME LC database was authorized by the French data protection authority (initial authorization no. DE-2017-397 and subsequent amendment in accordance with General Data Protection Regulation). The ESME Lung Cancer Scientific Committee specifically approved the present work. The ESME LC cohort is registered on under the number NCT03848052. In accordance with the authorizations issued by the French authorities for the ESME database and in compliance with the regulation in force for such retrospective registry, no formal dedicated informed consent is required. All data were obtained retrospectively, and all patients have approved the use of their data. The entrectinib data were aggregate and are considered anonymous. As a result, the data do not fall within the scope of the General Data Protection Regulation and no additional patient information or consent is required. The original databases were set up in accordance with the regulations (patient consent) but are out of scope for this study.”

: Not applicable.

: TF reported receiving personal fees from Jansen outside the submitted work; institutional fees from Roche, Lilly outside the submitted work. MP has been compensated for participating in advisory boards and giving presentations for Roche, Pfizer, Takeda and AnHeart Therapeutics, and has served as a principal investigator in trials sponsored by Roche, Takeda and AnHeart Therapeutics.CE, LoB, LiB, VB, GC, KT, DP and MM declare that they have no conflict of interest.